Prognostic Value of IMP3 and Its Role as an Epithelial-Mesenchymal Transition Promoter in Breast Carcinoma
Tóm tắt
Từ khóa
Tài liệu tham khảo
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E586
International Agency for Research on Cancer, World Health Organisation (WHO). World Fact Sheet, Globocan 2020 [Internet]. 2021 [Updated 2021 Mar, cited 2021 Mar 21]. https://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf
Masoud V, Pagès G (2017) Targeted therapies in breast cancer: new challenges to fight against resistance. J. Clin. Oncol 8(2):120–134
Kaarthigeyan K (2012) Cervical cancer in India and HPV vaccination. Indian J. Med. Paediatr. Oncol 33(1):7–12
Chen L, Xie Y, Li X, Gu L, Gao Y, Tang L et al (2017) Prognostic value of high IMP3 expression in solid tumors: a meta-analysis. Onco Targets Ther 10:2849–2863
Putti TC, Abd El-Rehim DM, Rakha EA, Paish CE, Lee AHS, Pinder SE et al (2005) Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18(1):26–35
Grzegrzolka J, Biala M, Wojtyra P, Kobierzycki C, Olbromski M, Gomulkiewicz A et al (2015) Expression of EMT markers SLUG and TWIST in breast cancer. Anticancer Res 35(7):3961–3968
Russell H, Pranjol MZI (2018) Transcription factors controlling E-cadherin downregulation in ovarian cancer. Biosci Horizons 11:1–6
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ (2009) Thresholds for therapies: Highlights of the St Gallen international expert consensus on the primary therapy of early breast cancer. Ann Oncol 20(8):1319–1329
Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL et al (2020) Estrogen and progesterone receptor testing in breast cancer: American Society Of Clinical Oncology/College of American Pathologists guideline update. Arch Pathol Lab Med 144(5):545–563
Wolff AC, McShane LM, Hammond MEH, Allison KH, Fitzgibbons P, Press MF et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. Arch Pathol Lab Med 142:1364–1382
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 71:209–249
(2005) Early Breast Cancer Trialists’ Colloborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomized trials. Lancet 365:1687–1717
Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M et al (2011) Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10 801 women in 17 randomised trials. Lancet 378(9804):1707–1716
Yuan RH, Wang CC, Chou CC, Chang KJ, Lee PH, Jeng YM (2009) Diffuse expression of RNA-binding protein IMP3 predicts high-stage lymph node metastasis and poor prognosis in colorectal adenocarcinoma. Ann Surg Oncol 16(6):1711–1719
Walter O, Prasad M, Lu S, Quinlan RM, Edmiston KL, Khan A (2009) IMP3 is a novel biomarker for triple negative invasive mammary carcinoma associated with a more aggressive phenotype. Hum Pathol 40(11):1528–1533
Mohanty SK, Lai JP, Gordon OK, Pradhan D, Bose S, Dadmanesh F (2015) BRCA-mutated invasive breast carcinomas: immunohistochemical analysis of insulin-like growth factor II mRNA-binding protein (IMP3), cytokeratin 8/18, and cytokeratin 14. Breast J 21(6):596–603
Sjekloča N, Tomić S, Mrklić I, Vukmirović F, Vučković L, Lovasić IB et al (2020) Prognostic value of IMP3 immunohistochemical expression in triple negative breast cancer. Med 99(7):1–7
Zhang HL, Eom T, Oleynikov Y, Shenoy SM, Liebelt DA, Dictenberg JB et al (2001) Neurotrophin-induced transport of a β-actin mRNP complex increases β-actin levels and stimulates growth cone motility. Neuron 31(2):261–275
Jiang Z, Lohse CM, Chu PG, Wu CL, Woda BA, Rock KL et al (2008) Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 112(12):2676–2682
Huang QD, Zheng SR, Cai YJ, Chen DL, Shen YY, Lin CQ et al (2018) IMP3 promotes TNBC stem cell property through miRNA-34a regulation. Eur Rev Med Pharmacol Sci 22(9):2688–2696
Yeap I, Mills J, Mylchreest L, Raut A, Gill AJ (2015) 18. IMP3 expression in triple-negative breast cancer. Pathology 47:S106
Gu S, Chu C, Chen W, Ren H, Cao Y, Li X et al (2019) Prognostic value of epithelial-mesenchymal transition related genes: SLUG and QKI in breast cancer patients. Int J Clin Exp Pathol 12(6):2009–2021
Fouad MA, Abdelhady WA, Elekiabi OA (2018) Chronicle of medicine and surgery SLUG & YKL-40 immunohistochemical expression in invasive ductal carcinoma of the breast ( IDC); clinicopathological values. COMS 2(4):206–218
Prasad CP, Rath G, Mathur S, Bhatnagar D, Parshad R, Ralhan R (2009) Expression analysis of E-cadherin, slug and GSK3β in invasive ductal carcinoma of breast. BMC Cancer 9:1–10
Zhang Z, Wang Y, Xie X, Peng J, Wei X, Huang D, et al. Prognostic and clinicopathological value of slug expression in breast cancer: a meta-analysis. Preprint 2021. https://doi.org/10.21203/rs.3.rs-651928/v1
Côme C, Magnino F, Bibeau F, De Santa BP, Becker KF, Theillet C, Savagner P (2006) Snail and slug play distinct roles during breast carcinoma progression. Clin Cancer Res 12(18):5395–53402
Medici D, Hay ED, Olsen BR (2008) Snail and slug promote epithelial-mesenchymal transition through β-catenin-T-cell factor-4-dependent expression of transforming growth factor-β3. Mol Biol Cell 19(11):4875–4887
Su P, Hu J, Zhang H, Li W, Jia M, Zhang X et al (2014) IMP3 expression is associated with epithelial-mesenchymal transition in breast cancer. Int J Clin Exp Pathol 7(6):3008–3017